HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC review agenda

This article was originally published in The Rose Sheet

Executive Summary

FDA expects to release the OTC Sunscreen Drug Products Final Monograph in November, according to the Department of Health & Human Services Semiannual Regulatory Agenda, published June 28 in the Federal Register. Rule previously was slated for release this spring following a delay last year to incorporate testing and labeling requirements for UVA/UVB (1"The Rose Sheet" June 9, 2003, p. 3). Final action on the antiperspirant monograph is expected in September, while the agency anticipates publishing technical amendments to the OTC skin protectant drugs final rule in December that permit optional labeling language to include the indications "helps prevent" and "chafed." Also on the agenda is the release of a notice of proposed rulemaking for labeling on convenience-size packaging in August...
Advertisement

Related Content

Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations
Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations
Advertisement
UsernamePublicRestriction

Register

RS012269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel